Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for inflammatory respiratory disease therapy verekitug.
Further signs that the biotech initial public offering (IPO) market is picking up have come with a filing by MBX Biosciences, seeking around $100 million to take a hypoparathyroidism candid
Just a few months after raising $200 million in third-round financing, immunology specialist Zenas BioPharma has filed an initial public offering in the US seeking to add another $100 milli
After abandoning its first initial public offering (IPO) filed in 2021, natural killer (NK) cell therapy specialist Artiva Biotherapeutics is having another go.
Just days after Telix priced a $200 million initial public offering (IPO) in the US, the Australian radiopharmaceutical specialist has abandoned the plan.